The 2024 DIA conference held a session on Harnessing Real-World Data to Generate Real-World Evidence for Clinical Trial Regulatory...

Gilead Sciences’ pivotal Phase 3 PURPOSE 1 trial has revealed compelling efficacy and safety results for lenacapavir, a novel...

The AFFINE study evaluating giroctocogene fitelparvovec, a gene therapy for moderate to severe hemophilia A, has achieved significant results....

A groundbreaking alliance between Worldwide Clinical Trials (Worldwide), Centrum Badan Klinicznych PI-House, and the Polish Psychedelic Society (PTP) aims...

BeiGene, a global oncology company, has established its flagship U.S. facility in Hopewell, New Jersey, aiming to bolster its...

ViiV Healthcare’s PASO DOBLE study found that the 2-drug regimen Dovato (DTG/3TC) is as effective as the 3-drug regimen...

Azitra, Inc., a biopharmaceutical company specializing in dermatology, has secured a U.S. patent (No. 12,036,248) for its potential treatment...

Vividion Therapeutics expands its global reach by establishing a new research and development (R&D) center and corporate headquarters in...

A five-year Master Services Agreement (MSA) has been signed between ViroCell Biologics and a prominent U.S. NCI-designated cancer center....

In an exclusive interview with Paul Crowe, CEO of NuView, we delve into his perspectives driving the upcoming Phase...